StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen WEZLANA / WEZENLA (ustekinumab-auub by Quarter

WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

Amgen WEZLANA / WEZENLA (ustekinumab-auub: $61M in Q2 2026, up 74.3% from a year earlier.

Latest, Q2 2026
61
Period ended Jun 30, 2026
Change on a year earlier
+74.3%
35 in Q2 2025
History
9 quarters
Since Q1 2024
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

“|| WEZLANA ® /WEZENLA ™ | — | 61 | 61 | 35 | 74%”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202661+74.3%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202647-68.7%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 202544+109.5%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202544+780.0%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202535–Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025150+14,900.0%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 202421–Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 20245–Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q1 2024Mar 31, 20241–Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗

Breakdown

What makes up WEZLANA / WEZENLA (ustekinumab-auub

Cite this data

StockData. (2026). Amgen WEZLANA / WEZENLA (ustekinumab-auub ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-wezlana-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.